Matricellular proteins in the heart: Possible role during stress and remodeling

Cardiovascular Research

Volumn 64, Issue 1, 2004, Pages 24-31

  Schellings, Mark W M ^a   Pinto, Yigal M ^a   Heymans, Stephane ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Extracellular matrix; Glycoproteins; Matricellular proteins; Matrix metalloproteinases; Remodelling

Indexed keywords

OSTEONECTIN; OSTEOPONTIN; SCLEROPROTEIN; TENASCIN; TENASCIN X; THROMBOSPONDIN 1; THROMBOSPONDIN 2; UNCLASSIFIED DRUG;

CELL FUNCTION; EMBRYO DEVELOPMENT; EXTRACELLULAR MATRIX; HEART INJURY; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART STRESS; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STRESS; UPREGULATION;

EXTRACELLULAR MATRIX PROTEINS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIUM; VENTRICULAR REMODELING;

EID: 4444315888     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.06.006     Document Type: Review

References (95)

1. Bornstein P., Sage E.H. Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 14:2002;608-616
2. Murphy-Ullrich J.E. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J. Clin. Invest. 107:2001;785-790
3. Mao J.R., Taylor G., Dean W.B., et al. Tenascin-X deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen deposition. Nat. Genet. 30:2002;421-425
4. Kyriakides T.R., Zhu Y.H., Smith L.T., et al. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J. Cell Biol. 140:1998;419-430
5. Bradshaw A.D., Reed M.J., Sage E.H. SPARC-null mice exhibit accelerated cutaneous wound closure. J. Histochem. Cytochem. 50:2002;1-10
6. Basu A., Kligman L.H., Samulewicz S.J., Howe C.C. Impaired wound healing in mice deficient in a matricellular protein SPARC (osteonectin BM-40). BMC Cell Biol. 2:2001;15
7. Giachelli C.M., Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 19:2000;615-622
8. Chiquet-Ehrismann R., Chiquet M. Tenascins: regulation and putative functions during pathological stress. J. Pathol. 200:2003;488-499
9. Kyriakides T.R., Tam J.W., Bornstein P. Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J. Invest. Dermatol. 113:1999;782-787
10. Jones F.S., Jones P.L. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev. Dyn. 218:2000;235-259
11. Crossin K.L., Hoffman S., Grumet M., et al. Site-restricted expression of cytotactin during development of the chicken embryo. J. Cell Biol. 102:1986;1917-1930
12. Imanaka-Yoshida K., Hiroe M., Nishikawa T., et al. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab. Invest. 81:2001;1015-1024
13. Jones P.L., Jones F.S. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol. 19:2000;581-596
14. Bristow J., Tee M.K., Gitelman S.E., et al. Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B. J. Cell Biol. 122:1993;265-278
15. Geffrotin C., Garrido J.J., Tremet L., Vaiman M. Distinct tissue distribution in pigs of tenascin-X and tenascin-C transcripts. Eur. J. Biochem. 231:1995;83-92
16. Matsumoto K., Takahashi K., Yoshiki A., et al. Invasion of melanoma in double knockout mice lacking tenascin-X and tenascin-C. Jpn. J. Cancer Res. 93:2002;968-975
17. Matsumoto K., Takayama N., Ohnishi J., et al. Tumour invasion and metastasis are promoted in mice deficient in tenascin-X. Genes Cells. 6:2001;1101-1111
18. Ikuta T., Ariga H., Matsumoto K. Extracellular matrix tenascin-X in combination with vascular endothelial growth factor B enhances endothelial cell proliferation. Genes Cells. 5:2000;913-927
19. Ikuta T., Ariga H., Matsumoto K.I. Effect of tenascin-X together with vascular endothelial growth factor A on cell proliferation in cultured embryonic hearts. Biol. Pharm. Bull. 24:2001;1320-1323
20. Schalkwijk J., Zweers M.C., Steijlen P.M., et al. A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. N. Engl. J. Med. 345:2001;1167-1175
21. Sato I., Shimada K. Quantitative analysis of tenascin in chordae tendineae of human left ventricular papillary muscle with aging. Ann. Anat. 183:2001;443-448
22. Imanaka-Yoshida K., Hiroe M., Yasutomi Y., et al. Tenascin-C is a useful marker for disease activity in myocarditis. J. Pathol. 197:2002;388-394
23. Willems I.E., Arends J.W., Daemen M.J. Tenascin and fibronectin expression in healing human myocardial scars. J. Pathol. 179:1996;321-325
24. Frangogiannis N.G., Shimoni S., Chang S.M., et al. Active interstitial remodeling: an important process in the hibernating human myocardium. J. Am. Coll. Cardiol. 39:2002;1468-1474
25. Tamura A., Kusachi S., Nogami K., et al. Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: distribution along margin of fibrotic lesions. Heart. 75:1996;291-294
26. Tremble P., Chiquet-Ehrismann R., Werb Z. The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol. Biol. Cell. 5:1994;439-453
27. Heymans S., Luttun A., Nuyens D., et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med. 5:1999;1135-1142
28. Ducharme A., Frantz S., Aikawa M., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest. 106:2000;55-62
29. Rohde L.E., Ducharme A., Arroyo L.H., et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 99:1999;3063-3070
30. Weber K.T. Fibrosis and hypertensive heart disease. Curr. Opin. Cardiol. 15:2000;264-272
31. Oberhauser A.F., Marszalek P.E., Erickson H.P., Fernandez J.M. The molecular elasticity of the extracellular matrix protein tenascin. Nature. 393:1998;181-185
32. Murphy-Ullrich J.E., Lightner V.A., Aukhil I., et al. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J. Cell Biol. 115:1991;1127-1136
33. Matsumoto K., Saga Y., Ikemura T., et al. The distribution of tenascin-X is distinct and often reciprocal to that of tenascin-C. J. Cell Biol. 125:1994;483-493
34. Lane T.F., Sage E.H. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J. 8:1994;163-173
35. Holland P.W., Harper S.J., McVey J.H., Hogan B.L. In vivo expression of mRNA for the Ca++-binding protein SPARC (osteonectin) revealed by in situ hybridization. J. Cell Biol. 105:1987;473-482
36. Sage H., Vernon R.B., Decker J., et al. Distribution of the calcium-binding protein SPARC in tissues of embryonic and adult mice. J. Histochem. Cytochem. 37:1989;819-829
37. Komatsubara I., Murakami T., Kusachi S., et al. Spatially and temporally different expression of osteonectin and osteopontin in the infarct zone of experimentally induced myocardial infarction in rats. Cardiovasc. Pathol. 12:2003;186-194
38. Stanton L.W., Garrard L.J., Damm D., et al. Altered patterns of gene expression in response to myocardial infarction. Circ. Res. 86:2000;939-945
39. Porter P.L., Sage E.H., Lane T.F., et al. Distribution of SPARC in normal and neoplastic human tissue. J. Histochem. Cytochem. 43:1995;791-800
40. Brekken R.A., Sage E.H. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 19:2001;816-827
41. Aeschlimann D., Kaupp O., Paulsson M. Transglutaminase-catalyzed matrix cross-linking in differentiating cartilage: identification of osteonectin as a major glutaminyl substrate. J. Cell Biol. 129:1995;881-892
42. Ledda F., Bravo A.I., Adris S., et al. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J. Invest. Dermatol. 108:1997;210-214
43. Massi D., Franchi A., Borgognoni L., et al. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum. Pathol. 30:1999;339-344
44. Rempel S.A., Ge S., Gutierrez J.A. SPARC: a potential diagnostic marker of invasive meningiomas. Clin. Cancer Res. 5:1999;237-241
45. Rempel S.A., Golembieski W.A., Ge S., et al. SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J. Neuropathol. Exp. Neurol. 57:1998;1112-1121
46. Gilles C., Bassuk J.A., Pulyaeva H., et al. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. 58:1998;5529-5536
47. Jacob K., Webber M., Benayahu D., Kleinman H.K. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res. 59:1999;4453-4457
48. Murphy-Ullrich J.E., Lane T.F., Pallero M.A., Sage E.H. SPARC mediates focal adhesion disassembly in endothelial cells through a follistatin-like region and the Ca(2+)-binding EF-hand. J. Cell. Biochem. 57:1995;341-350
49. Masson S., Arosio B., Luvara G., et al. Remodelling of cardiac extracellular matrix during beta-adrenergic stimulation: upregulation of SPARC in the myocardium of adult rats. J. Mol. Cell. Cardiol. 30:1998;1505-1514
50. Bradshaw A.D., Sage E.H. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J. Clin. Invest. 107:2001;1049-1054
51. Yan Q., Sage E.H. SPARC, a matricellular glycoprotein with important biological functions. J. Histochem. Cytochem. 47:1999;1495-1506
52. Kupprion C., Motamed K., Sage E.H. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J. Biol. Chem. 273:1998;29635-29640
53. Carmeliet P., Collen D. Transgenic mouse models in angiogenesis and cardiovascular disease. J. Pathol. 190:2000;387-405
54. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257
55. Edelberg J.M., Cai D., Xaymardan M. Translation of PDGF cardioprotective pathways. Cardiovasc. Toxicol. 3:2003;27-35
56. Thayer J.M., Giachelli C.M., Mirkes P.E., Schwartz S.M. Expression of osteopontin in the head process late in gastrulation in the rat. J. Exp. Zool. 272:1995;240-244
57. Giachelli C., Schwartz S.M., Liaw L. Molecular and cellular biology of osteopontin. Trends Cardiovasc. Med. 5:1995;88-95
58. Denhardt D.T., Guo X. Osteopontin: a protein with diverse functions. FASEB J. 7:1993;1475-1482
59. Tuck A.B., O'Malley F.P., Singhal H., et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch. Pathol. Lab. Med. 121:1997;578-584
60. Giachelli C.M., Bae N., Almeida M., et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Invest. 92:1993;1686-1696
61. Trueblood N.A., Xie Z., Communal C., et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ. Res. 88:2001;1080-1087
62. Ellison J.A., Velier J.J., Spera P., et al. Osteopontin and its integrin receptor alpha(v)beta3 are upregulated during formation of the glial scar after focal stroke. Stroke. 29:1998;1698-1706. [discussion 1707]
63. O'Brien E.R., Garvin M.R., Stewart D.K., et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler. Thromb. 14:1994;1648-1656
64. Mazzali M., Kipari T., Ophascharoensuk V., et al. Osteopontin - a molecule for all seasons. QJM. 95:2002;3-13
65. Nasu K., Ishida T., Setoguchi M., et al. Expression of wild-type and mutated rabbit osteopontin in Escherichia coli, and their effects on adhesion and migration of P388D1 cells. Biochem. J. 307(Pt 1):1995;257-265
66. Giachelli C.M., Lombardi D., Johnson R.J., et al. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am. J. Pathol. 152:1998;353-358
67. Ashkar S., Weber G.F., Panoutsakopoulou V., et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 287:2000;860-864
68. Nau G.J., Liaw L., Chupp G.L., et al. Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin. Infect. Immun. 67:1999;4223-4230
69. Crawford H.C., Matrisian L.M., Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res. 58:1998;5206-5215
70. Denhardt D.T., Noda M., O'Regan A.W., et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest. 107:2001;1055-1061
71. Liaw L., Birk D.E., Ballas C.B., et al. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J. Clin. Invest. 101:1998;1468-1478
72. Graf K., Do Y.S., Ashizawa N., et al. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation. 96:1997;3063-3071
73. Rocha R., Rudolph A.E., Frierdich G.E., et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 283:2002;H1802-H1810
74. Singh K., Sirokman G., Communal C., et al. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension. 33:1999;663-670
75. Murry C.E., Giachelli C.M., Schwartz S.M., Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am. J. Pathol. 145:1994;1450-1462
76. Williams E.B., Halpert I., Wickline S., et al. Osteopontin expression is increased in the heritable cardiomyopathy of Syrian hamsters. Circulation. 92:1995;705-709
77. Xie Z., Singh M., Siwik D.A., et al. Osteopontin inhibits interleukin-1beta-stimulated increases in matrix metalloproteinase activity in adult rat cardiac fibroblasts: role of protein kinase C-zeta. J. Biol. Chem. 278:2003;48546-48552
78. Iruela-Arispe M.L., Liska D.J., Sage E.H., Bornstein P. Differential expression of thrombospondin 1, 2, and 3 during murine development. Dev. Dyn. 197:1993;40-56
79. Kyriakides T.R., Zhu Y.H., Yang Z., Bornstein P. The distribution of the matricellular protein thrombospondin 2 in tissues of embryonic and adult mice. J. Histochem. Cytochem. 46:1998;1007-1015
80. Tooney P.A., Sakai T., Sakai K., et al. Restricted localization of thrombospondin-2 protein during mouse embryogenesis: a comparison to thrombospondin-1. Matrix Biol. 17:1998;131-143
81. Crawford S.E., Stellmach V., Murphy-Ullrich J.E., et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 93:1998;1159-1170
82. Good D.J., Polverini P.J., Rastinejad F., et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. U. S. A. 87:1990;6624-6628
83. Iruela-Arispe M.L., Lombardo M., Krutzsch H.C., et al. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation. 100:1999;1423-1431
84. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J. Cell. Mol. Med. 6:2002;1-12
85. Murphy-Ullrich J.E., Hook M. Thrombospondin modulates focal adhesions in endothelial cells. J. Cell Biol. 109:1989;1309-1319
86. Greenwood J.A., Murphy-Ullrich J.E. Signaling of de-adhesion in cellular regulation and motility. Microsc. Res. Tech. 43:1998;420-432
87. Agah A., Kyriakides T.R., Lawler J., Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am. J. Pathol. 161:2002;831-839
88. Murphy-Ullrich J.E., Gurusiddappa S., Frazier W.A., Hook M. Heparin-binding peptides from thrombospondins 1 and 2 contain focal adhesion-labilizing activity. J. Biol. Chem. 268:1993;26784-26789
89. Pellerin S., Lafeuillade B., Chambaz E.M., Feige J.J. Distinct effects of thrombospondin-1 and CISP/thrombospondin-2 on adrenocortical cell spreading. Mol. Cell. Endocrinol. 106:1994;181-186
90. Yang Z., Kyriakides T.R., Bornstein P. Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2. Mol. Biol. Cell. 11:2000;3353-3364
91. Cleutjens J., Huynen F., Smits J., et al. Thrombospondin-2 deficiency in mice results in cardiac rupture early after myocardial infarction. Circ. Res. 100:1999;156. [Suppl.]
92. Yang Z., Strickland D.K., Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J. Biol. Chem. 276:2001;8403-8408
93. Lee T., Esemuede N., Sumpio B.E., Gahtan V. Thrombospondin-1 induces matrix metalloproteinase-2 activation in vascular smooth muscle cells. J. Vasc. Surg. 38:2003;147-154
94. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ. Res. 90:2002;520-530
95. Forsberg E., Hirsch E., Frohlich L., et al. Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc. Natl. Acad. Sci. U. S. A. 93:1996;6594-6599